Publications

Recent peer-reviewed publications from our lab and collaborators,
with a complete bibliography available on PubMed.

Selected publications

2021 2022 2023 2024 2026

2026

Epidemiology and Outcomes of Bronchiectasis in Alberta, Canada: A 15-Year Population-Based Study.

Somayaji R, Black JE, Whitten TA, Gutierrez MW, Burke-Gaffney J, Cooper R, Jarand J, Leigh R, Smith M, Thornton CS

Ann Am Thorac Soc. · 2026;aaoag258

Global, regional, and national burden of HIV/AIDS, 1990-2023, with the estimated burden attributable to intimate partner violence and forecasted impacts of funding cuts through 2030: results from the Global Burden of Disease Study 2023.

GBD 2023 HIV Collaborators

Lancet HIV. · 2026;S2352-3018(26)00147-5

Spore Wars: A Comprehensive Review of Pulmonary Aspergilloma and Its Clinical Management.

Seo C, Dumoulin E, Thornton CS

Chest. · 2026;170(2):365-375

Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

GBD 2023 TB HIV Collaborators

Lancet Infect Dis. · 2026;S1473-3099(26)00295-1

Density fluctuations of Burkholderia and Achromobacter in cystic fibrosis sputum.

Carmody LA, Caverly LJ, Kalikin LM, Thornton CS, Simon RH, VanDevanter DR, LiPuma JJ

J Cyst Fibros. · 2026;25(4):651-654

Granules of truth: unpacking the eosinophilic endotype in bronchiectasis.

Arbiv OA, Thornton CS

Thorax. · 2026;81(7):621-622

Bridging the airway microbiome and targeted therapy in bronchiectasis: multi-omics insights, endotypes and emerging therapies.

Thornton CS, Schaupp L, Tunney MM, Mall MA

Eur Respir J. · 2026;68:2600239

The Guild Model of CF Airway Microbial Ecology.

Dunham SJB, Willkeen GA, Darby B, Corley JM, Hahn A, Klapper I, Bean HD, Caverly LJ, Thornton CS, Martin C, Quinn RA, Widder S, Bailey BA, Wagner BD, Garg N, Planet PJ, Hunter RC, LiPuma JJ, Rohwer F, Whiteson KL

mBio. · 2026;17(6):e0366825

Remodelling of cystic fibrosis respiratory microbiota in response to extended elexacaftor-tezacaftor-ivacaftor therapy.

Gavillet H, Hatfield LR, Hardman M, Marsh R, Einarsson GG, Thornton CS, Parkins MD, Duckers J, Bomberger JM, Hilliam Y, Lee SE, Lord RW, Jones A, Horsley A, Daniels TWV, Teneback CC, Rivett DW, van der Gast C

Microbiome. · 2026;14(1)

Microbiota, Mucus, and Modulators: Cystic Fibrosis Infection Pathogenesis in the Cystic Fibrosis Transmembrane Conductance Regulator Modulator Era.

Thornton CS, Bouzek DC, Caverly LJ

J Infect Dis. · 2026;233(4):631-639

A 67-year-old woman with bronchiectasis and acute worsening respiratory symptoms.

Arbiv OA, Thornton CS

CMAJ. · 2026;198(15):E592-E594

Effect of transient versus persistent Aspergillus colonisation on clinical outcomes in bronchiectasis.

Michaud A, Jarand J, Thornton CS

ERJ Open Res. · 2026;12(2):00732-2025

Rates and Characteristics of Bronchiectasis-Related Hospitalizations in the United States in 2022: A Population-Based Cohort Study.

Deviaene M, Haldane V, Black JE, Thornton CS, Somayaji R

Ann Am Thorac Soc. · 2026;aaoag018

Bronchoscopic debridement and antifungal therapy as an effective non-surgical approach to concomitant aspergilloma and ABPA: A case report.

Yeo SK, Thornton CS, Dumoulin E

Ther Adv Respir Dis. · 2026;20:17534666261480895

Isavuconazole as an adjunctive antifungal in the multimodal management of pulmonary aspergilloma and chronic cavitary pulmonary aspergillosis: a single-centre case series.

Deviaene M, Dumoulin E, Somayaji R, Mody CH, Thornton CS

Respir Med Case Rep. · 2026;63:102486

Sputum colour variability and clinical outcomes in bronchiectasis: a multicentre Canadian-UK study.

Thornton CS, Jackson L, Seo C, et al.

ERJ Open Res. · 2026;00735-2026

Sputum microbiome associates with Pseudomonas aeruginosa infection risk in cystic fibrosis.

Bowron LA, Waddell B, et al.

ERJ Open Res. · 2026;00553-2026

Cardiovascular risk assessment in patients with bronchiectasis: insights from the Canadian Bronchiectasis and NTM (CanBE-NTM) Registry.

Kim DH, Purighalla S, et al.

ERJ Open Res. · 2026;00091-2026

Characteristics and outcomes of adults with bronchiectasis due to primary ciliary dyskinesia: combined analysis of EMBARC, Australian, USA and Canadian registries.

Shoemark A, McShane PJ, et al.

SSRN (preprint). · 2026; not yet peer reviewed

2024

The Canadian Bronchiectasis and Nontuberculous Mycobacteria Registry: a study protocol.

Thornton CS, Boechler N, Desai V, Somayaji R, Purighalla S, Brode S, Marras TK, Cooper R, Smith M, Jarand J

ERJ Open Res. · 2024;10(6):00412-2024

2023

Microbial Epidemiology of the Cystic Fibrosis Airways: Past, Present, and Future.

Thornton CS, Parkins MD

Semin Respir Crit Care Med. · 2023;44(2):269-286

2022

Assessment of factors and interventions towards therapeutic adherence among persons with non-cystic fibrosis bronchiectasis.

Thornton CS, Somayaji R, Lim RK

ERJ Open Res. · 2022;8(4):00340-2022

Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation.

Thornton CS, Acosta N, Surette MG, Parkins MD

J Pediatric Infect Dis Soc. · 2022;11(Suppl 2):S13-S22

Human papillomavirus (HPV) and cervical dysplasia in adult female cystic fibrosis (CF) lung transplant recipients.

Thornton CS, Somayaji R, Chu A, Parkins MD

Thorax. · 2022;77(6):625-627

2021

Potential Contributions of Anaerobes in Cystic Fibrosis Airways.

Thornton CS, Surette MG

J Clin Microbiol. · 2021;59(3):e01813-19

Full paper list available on PubMed.